# OnCo record abl1-kinase-domain-mutations (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/abl1-kinase-domain-mutations/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "abl1-kinase-domain-mutations" ;
  schema:name "BCR::ABL1 kinase domain mutations (T315I and others)"@en ;
  schema:alternateName "T315I"@en, "T315I mutation"@en, "ABL1 kinase domain mutation"@en, "ABL kinase domain mutation"@en, "kinase domain mutations in CML"@en, "BCR-ABL1 mutation"@en, "BCR::ABL1 mutation analysis"@en, "kinase domain mutation analysis"@en, "compound BCR::ABL1 mutations"@en, "E255K"@en, "Y253H"@en, "F317L"@en, "V299L"@en, "F359V"@en, "myristoyl-pocket mutation"@en ;
  schema:description "When a CML drug stops working, the leukaemia has usually changed the shape of the pocket the drug fits into; sequencing the BCR::ABL1 kinase domain names the mutation, and the name tells the doctor which drug still fits: most mutations respond to another second-generation drug, but T315I responds only to ponatinib or asciminib."@en ;
  schema:url <https://onco.cc/terms/abl1-kinase-domain-mutations/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  onco:related <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/terms/philadelphia-chromosome/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/molecular-response/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/>, <https://onco.cc/drugs/dasatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/drugs/bosutinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/blinatumomab/> ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/cml-chronic-phase/>, <https://onco.cc/cancers/cml-advanced-phase/>, <https://onco.cc/cancers/all-paediatric-ph-positive/> .